BiDil: Assessing a race-based pharmaceutical

Howard Brody, Linda M. Hunt

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Isosorbide and hydralazine in a fixed-dose combination (BiDil) has provoked controversy as the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African Americans, in the treatment of congestive heart failure. Family physicians will be better prepared to counsel their patients about this new drug if they understand a number of background issues. The scientific research leading to BiDil's approval tested the drug only in African American populations, apparently for commercial reasons, so the drug's efficacy in other populations is unknown. Race as a biological-medical construct is increasingly controversial; BiDil offers a good example of how sociocultural factors in disease causation may be overlooked as a result of an overly simplistic assumption of a racial and hence presumed genetic difference. Past discrimination and present disparities in health care involving African American patients are serious concerns, and we must welcome a treatment that promises to benefit a previously underserved group; yet the negative aspects of BiDil and the process that led to its discovery and marketing set an unfortunate precedent. Primary care physicians should be aware of possible generic equivalents that will affect the availability of this drug for low-income or uninsured patients.

Original languageEnglish (US)
Pages (from-to)556-560
Number of pages5
JournalAnnals of Family Medicine
Volume4
Issue number6
DOIs
StatePublished - Nov 2006

Fingerprint

African Americans
Pharmaceutical Preparations
Healthcare Disparities
Isosorbide
Drug Approval
Hydralazine
Family Physicians
Primary Care Physicians
United States Food and Drug Administration
Marketing
Ethnic Groups
Causality
Population
Heart Failure
isosorbide-hydralazine combination
Therapeutics
Research

Keywords

  • Communication
  • Delivery of health care
  • Genetic predisposition to disease
  • Health services research
  • Heart failure, congestive
  • Minority groups

ASJC Scopus subject areas

  • Family Practice

Cite this

BiDil : Assessing a race-based pharmaceutical. / Brody, Howard; Hunt, Linda M.

In: Annals of Family Medicine, Vol. 4, No. 6, 11.2006, p. 556-560.

Research output: Contribution to journalArticle

Brody, Howard ; Hunt, Linda M. / BiDil : Assessing a race-based pharmaceutical. In: Annals of Family Medicine. 2006 ; Vol. 4, No. 6. pp. 556-560.
@article{52fcb92afbae43468f18b0b7e4cd574f,
title = "BiDil: Assessing a race-based pharmaceutical",
abstract = "Isosorbide and hydralazine in a fixed-dose combination (BiDil) has provoked controversy as the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African Americans, in the treatment of congestive heart failure. Family physicians will be better prepared to counsel their patients about this new drug if they understand a number of background issues. The scientific research leading to BiDil's approval tested the drug only in African American populations, apparently for commercial reasons, so the drug's efficacy in other populations is unknown. Race as a biological-medical construct is increasingly controversial; BiDil offers a good example of how sociocultural factors in disease causation may be overlooked as a result of an overly simplistic assumption of a racial and hence presumed genetic difference. Past discrimination and present disparities in health care involving African American patients are serious concerns, and we must welcome a treatment that promises to benefit a previously underserved group; yet the negative aspects of BiDil and the process that led to its discovery and marketing set an unfortunate precedent. Primary care physicians should be aware of possible generic equivalents that will affect the availability of this drug for low-income or uninsured patients.",
keywords = "Communication, Delivery of health care, Genetic predisposition to disease, Health services research, Heart failure, congestive, Minority groups",
author = "Howard Brody and Hunt, {Linda M.}",
year = "2006",
month = "11",
doi = "10.1370/afm.582",
language = "English (US)",
volume = "4",
pages = "556--560",
journal = "Annals of Family Medicine",
issn = "1544-1709",
publisher = "Annals of Family Medicine, Inc",
number = "6",

}

TY - JOUR

T1 - BiDil

T2 - Assessing a race-based pharmaceutical

AU - Brody, Howard

AU - Hunt, Linda M.

PY - 2006/11

Y1 - 2006/11

N2 - Isosorbide and hydralazine in a fixed-dose combination (BiDil) has provoked controversy as the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African Americans, in the treatment of congestive heart failure. Family physicians will be better prepared to counsel their patients about this new drug if they understand a number of background issues. The scientific research leading to BiDil's approval tested the drug only in African American populations, apparently for commercial reasons, so the drug's efficacy in other populations is unknown. Race as a biological-medical construct is increasingly controversial; BiDil offers a good example of how sociocultural factors in disease causation may be overlooked as a result of an overly simplistic assumption of a racial and hence presumed genetic difference. Past discrimination and present disparities in health care involving African American patients are serious concerns, and we must welcome a treatment that promises to benefit a previously underserved group; yet the negative aspects of BiDil and the process that led to its discovery and marketing set an unfortunate precedent. Primary care physicians should be aware of possible generic equivalents that will affect the availability of this drug for low-income or uninsured patients.

AB - Isosorbide and hydralazine in a fixed-dose combination (BiDil) has provoked controversy as the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African Americans, in the treatment of congestive heart failure. Family physicians will be better prepared to counsel their patients about this new drug if they understand a number of background issues. The scientific research leading to BiDil's approval tested the drug only in African American populations, apparently for commercial reasons, so the drug's efficacy in other populations is unknown. Race as a biological-medical construct is increasingly controversial; BiDil offers a good example of how sociocultural factors in disease causation may be overlooked as a result of an overly simplistic assumption of a racial and hence presumed genetic difference. Past discrimination and present disparities in health care involving African American patients are serious concerns, and we must welcome a treatment that promises to benefit a previously underserved group; yet the negative aspects of BiDil and the process that led to its discovery and marketing set an unfortunate precedent. Primary care physicians should be aware of possible generic equivalents that will affect the availability of this drug for low-income or uninsured patients.

KW - Communication

KW - Delivery of health care

KW - Genetic predisposition to disease

KW - Health services research

KW - Heart failure, congestive

KW - Minority groups

UR - http://www.scopus.com/inward/record.url?scp=33845502068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845502068&partnerID=8YFLogxK

U2 - 10.1370/afm.582

DO - 10.1370/afm.582

M3 - Article

C2 - 17148635

AN - SCOPUS:33845502068

VL - 4

SP - 556

EP - 560

JO - Annals of Family Medicine

JF - Annals of Family Medicine

SN - 1544-1709

IS - 6

ER -